Kolltan Pharmaceuticals to Present Preclinical Data at the 2016 American Association for Cancer Research (AACR) Annual Meeting

Preclinical data to be presented for KTN3379 and KTN0158 clinical-stage programs

Preclinical data to be presented for ALK-ADC and MET research programs

NEW HAVEN, Conn.--()--Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for use in oncology and immunology, today announced oral and poster presentations of key preclinical data relating to certain of its drug development programs, including KTN3379, KTN0158, ALK-ADC and MET, at the American Association for Cancer Research (AACR) Annual Meeting, which will take place in New Orleans, Louisiana, April 16-20, 2016.

Following are the specifics for the five poster presentations and one oral presentation at the AACR conference, including session times and authors:

Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN (Abstract Number 1196)
Authors: Gwenda Ligon, Jay Lillquist, Scott Seibel, Jerry Wallweber, Veronique Neumeister, David Rimm, Theresa LaVallee, Diego Alvarado. Kolltan Pharmaceuticals, Inc., New Haven, CT; Monogram Biosciences/ LabCorp, South San Francisco, CA; Yale University, New Haven, CT
Session Category: Experimental and Molecular Therapeutics
Session Title: Growth Factor Receptors and Surface Antigens as Therapeutic Targets
Session Date/ Time: Monday, April 18, 2016, 8:00 AM to 12:00 PM CDT
Location: Morial Convention Center, Halls G-J, Poster Section 15, Poster Board #5

A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastoma (Abstract Number 2690)
Speaker: Renata Sano, Scientist, University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia
Authors: Renata Sano, Kateryna Krytska, Colleen Larmour, Gwenda Ligon, Jay Lillquist, Ulisse Cucchi, Paolo Orsini, Simona Rizzi, Gerald McMahon, Diego Alvarado, Yael P. Mosse. Children's Hospital of Philadelphia, Philadelphia, PA; Kolltan Pharmaceuticals, Inc., New Haven, CT; Nerviano Medical Sciences, Nerviano, Italy
Session Type: Minisymposium
Session Title: Molecular Advances in Pediatric Cancer
Session Date/ Time: Monday, April 18, 2016, 3:05 PM to 3:20 PM CDT
Location: Morial Convention Center, Room 354

Inhibition of heregulin-mediated ErbB3 signaling as a radiosensitization therapy for head and neck cancers (Abstract Number 3053)
Authors: Marta Baro, Josep Balart, Joseph Contessa. Yale University, New Haven, CT; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Session Category: Experimental and Molecular Therapeutics
Session Title: Oncogenes and Tumor Suppressor Genes as Therapeutic Targets
Session Date/ Time: Tuesday, April 19, 2016, 8:00 AM to 12:00 PM CDT
Location: Morial Convention Center, Poster Section 13, Poster Board #13

Dual targeting of HER3 and PIK3CA has potent anti-tumor effects in pre-clinical models of HNSCC (Abstract Number 2979)
Authors: Nayel Khan, Kara Davis, Neal Godse, Carolyn Kemp, Sucheta Kulkarni, Diego Alvarado, Theresa LaVallee, Jennifer Grandis, Umamaheswar Duvvuri. University of Pittsburgh Medical Center, Pittsburgh, PA; Kolltan Pharmaceuticals, Inc., New Haven, CT
Session Category: Experimental and Molecular Therapeutics
Session Title: Oncogenes and Tumor Suppressor Genes as Therapeutic Targets
Session Date/ Time: Tuesday, April 19, 2016, 8:00 AM to 12:00 PM CDT
Location: Morial Convention Center, Poster Section 15, Poster Board #25

Inhibition of KIT in vivo modifies immune cell populations to improve the efficacy of checkpoint inhibitors in syngeneic mouse tumor models (Abstract Number 4020)
Authors: Andrew Garton, Lori Lopresti-Morrow, Scott Seibel, Theresa LaVallee, Richard Gedrich. Kolltan Pharmaceuticals, Inc., New Haven, CT
Session Category: Immunology
Session Title: Mechanisms and Applications of Immune-based Therapies
Session Date/ Time: Tuesday, April 19, 2016, 1:00 PM to 5:00 PM CDT
Location: Morial Convention Center, Halls G-J, Poster Section 27, Poster Board #3

An anti-MET IgG2 monoclonal antibody degrades both wild-type and exon 14 mutant MET receptor tyrosine kinase through a novel exon 14-independent mechanism and inhibits tumor growth (Abstract Number 3835)
Authors: Brett Robinson, Sreekala Mandiyan, Gerald McMahon, Yan Yang. Kolltan Pharmaceuticals, Inc., New Haven, CT
Session Category: Experimental and Molecular Therapeutics
Session Title: Oncogenes and Tumor Suppressor Genes as Therapeutic Targets
Session Date/ Time: Tuesday, April 19, 2016, 1:00 PM to 5:00 PM CDT
Location: Morial Convention Center, Poster Section 18, Poster Board #22

About KTN3379

KTN3379 is a human monoclonal antibody designed to block the activity of ErbB3 (HER3), a receptor tyrosine kinase (RTK) that belongs to the epidermal growth factor receptor, or EGFR, family. ErbB3 is believed to be an important receptor regulating cancer cell growth and survival. ErbB3 is expressed in many cancers, including head and neck, breast, lung, gastric, and melanoma. Kolltan is conducting multiple clinical trials evaluating KTN3379 in the treatment of solid tumors (NCT02014909, NCT02456701, and NCT02473731).

About KTN0158

KTN0158 is a proprietary, humanized monoclonal antibody designed using structure-based approaches to block the activation of KIT, an RTK that is expressed on many cancers and mast cells. There are currently no KIT-targeting antibodies on the market for any disease indication. In oncology, KIT is expressed in tumors such as GIST, melanoma, AML, SCLC, and others. Additionally, KIT is expressed in immune suppressive cells in the tumor microenvironment and thus may provide a novel combination treatment for immuno-oncology. Kolltan has initiated a Phase 1 study for the treatment of GIST and other KIT-expressing tumors (NCT02642016) and plans to move into combination studies with other targeted therapies and T cell checkpoint inhibitors.

About Kolltan Pharmaceuticals

Kolltan, a privately held clinical-stage company, is focused on the discovery and development of novel, antibody-based drugs targeting RTKs for the treatment of cancer and other diseases with significant unmet need. Kolltan’s founders and members of its management team have deep expertise and a proven track record in drug discovery, development, and commercialization of innovative therapeutics, including drugs targeting RTKs. Kolltan is working in close collaboration with the laboratory of Kolltan Co-Founder Dr. Joseph Schlessinger, as well as the Yale University medical and scientific community. The Company has a broad and novel oncology and immunology portfolio of therapeutic biologics targeting multiple RTKs that are advancing in the clinic and are expected to generate multiple near-term milestones.

Forward Looking Statements Disclosure

Any statements in this news release about future expectations, plans, and prospects for Kolltan constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of a variety of important factors. Kolltan anticipates that subsequent events and developments may cause its views to change. However, while Kolltan may elect to update these forward-looking statements in the future, Kolltan specifically disclaims any obligation to do so.

Contacts

Media Inquiries:
Burns McClellan
Justin Jackson, 212-213-0006
jjackson@burnsmc.com
or
Investor Inquiries:
Kolltan Pharmaceuticals, Inc.
Jay Campbell, 203-907-0938
jay.campbell@kolltan.com

Contacts

Media Inquiries:
Burns McClellan
Justin Jackson, 212-213-0006
jjackson@burnsmc.com
or
Investor Inquiries:
Kolltan Pharmaceuticals, Inc.
Jay Campbell, 203-907-0938
jay.campbell@kolltan.com